That same study, funded by Novo Nordisk, showed participants lost about 15% of their body weight after taking semaglutide for 16 months, compared to a 2.4% weight loss for those taking a placebo
The benefit was not observed in all-cause death (HR 0.99, 95% CI 0.841.15), hospitalization for heart failure (HR 1.04, 95% CI 0.891.22), cardiovascular death (HR 0.95, 95% CI 0.791.16), myocardial infarction (HR 0.88, 95% CI 0.711.08), stroke (HR 1.03, 95% CI 0.751.43) and death or hospitalization for HF (HR 1.07, 95% CI 0.781.46)
Heres a dosing schedule
Endothelial deficiency of insulin-like growth factor-1 receptor (IGF1R) impairs neurovascular coupling responses in mice, mimicking aspects of the brain aging phenotype
* Values represent the mean SD
This compound is not approved by the FDA for any use and is supplied strictly for in-vitro laboratory research use only